fasudil has been researched along with Cardiometabolic Syndrome in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schinzari, F | 1 |
| Tesauro, M | 1 |
| Rovella, V | 1 |
| Di Daniele, N | 1 |
| Gentileschi, P | 1 |
| Mores, N | 1 |
| Campia, U | 1 |
| Cardillo, C | 1 |
1 other study available for fasudil and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Antioxidants; Drug Resistance; Endothelium, Va | 2012 |